Philips boosts digital pathology with enhanced informatics to advance precision diagnosis in oncology
December 04 2020 - 9:00AM
Philips boosts digital pathology with enhanced informatics to
advance precision diagnosis in oncology
December 4, 2020
Latest iteration of Philips IntelliSite Pathology Solution helps
support pathologists to work more efficiently in an automated
digital workflow
Amsterdam, The Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced it will introduce its latest advancements in digital
pathology at the European Congress of Pathology 2020 virtual event,
Dec. 6-8. Building on its strong portfolio to support oncology
clinical decision-making, Philips brings together the power of
imaging, pathology, genomics and longitudinal data with insights
from artificial intelligence, to empower clinicians to deliver
clear care pathways with predictable outcomes for every
patient.
Pathology is vital to healthcare delivery, with 70% of decisions
affecting a person’s life involving a laboratory or pathology test
[1]. However, with current resource shortages, the growing volume
of complex requests, and workflow inefficiencies across systems and
departments, pathology labs are facing major pressures on multiple
fronts.
Rather than viewing oncology as many single moments of care,
Philips envisions a continuous care pathway empowered by integrated
solutions for oncology and pathology that help transform and
enhance multi-disciplinary workflows, including the oncology tumor
board process. Critical patient data is made visible for both
oncologists and pathologists, which allows them to collaborate more
efficiently, to drive the right care in the right sequence at the
right time.
By taking a systems view across the imaging enterprise, Philips
leverages the power of smart diagnostic technologies and advanced
informatics to remove the obstacles standing in the way of
optimized workflows. The newly released Philips IntelliSite
Pathology Solution features a leading-edge user experience (UX),
enhancing ease of use while helping streamline the imaging workflow
in an automated digital solution. With this latest iteration,
Philips connects healthcare systems to scale digital operations and
improve efficiency in high volume scanning, stimulate collaboration
and enable precision diagnosis.
Philips commitment to an open pathology
platformPhilips IntelliSite Pathology Solution offers an
open, scalable, and interoperable platform that supports
flexibility in deployments of image analysis software tools,
strengthening Philips commitment to the Open Pathology platform.
Other software tools allow developers and researchers to work
with data natively in the iSyntax format for core research and
algorithm development, enabling collaboration for education and the
creation of third-party applications.
“A precise diagnosis informs the patient’s care pathway
progress, from screening and diagnosis to treatment, monitoring,
assessment, and the transition toward home care,” said Kees
Wesdorp, Chief Business Leader Precision Diagnosis at Philips.
”Philips integrated solutions for oncology, including this latest
enhancement in digital pathology, help empower the cancer care team
to reach clinical treatment decisions based on richer dashboards,
clinical images, reports, and structured patient data. The seamless
integration of information into the oncology workflow will help
improve the clinician experience and ultimately, patient
outcomes.”
Philips participation in the Virtual ECP 2020
CongressPhilips will host a virtual presence during the
32nd European Society of Pathology Congress (ECP 2020) from
December 6-8. ECP attendees will experience digital pathology
imaging through demonstrations and webinars. Dr. Juan Retamero, a
digital pathology professional, will share his experiences and
vision on how digital pathology brings great potential to enhance
patient care. Please visit www.philips.com/digitalpathology for
more information.
[1] Report of the Second Phase of the Review of NHS Pathology
Services in England, Lord Carter of Coles.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: +1
978-221-8919E-mail : kathy.oreilly@philips.comTwitter:
@kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Care team reviewing histopathology slides
- Pathologist reviewing histopathology slides
- Pathologist reviewing histopathology slides on 2 screens
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024